EP 1311237 A2 20030521 - USE OF CYCLIC 2,4-DIPHOSPHOGLYCERATES (CDGP) AND/OR DERIVATIVES THEREOF IN COSMETIC AND DERMATOLOGICAL FORMULATIONS
Title (en)
USE OF CYCLIC 2,4-DIPHOSPHOGLYCERATES (CDGP) AND/OR DERIVATIVES THEREOF IN COSMETIC AND DERMATOLOGICAL FORMULATIONS
Title (de)
VERWENDUNG VON CYCLISCHEM 2,4 DIPHOSPHOGLYCERAT (cDGP) UND/ODER DERIVATEN IN KOSMETISCHEN UND DERMATOLOGISCHEN FORMULIERUNGEN
Title (fr)
UTILISATION DE 2,4-DIPHOSPHOGLYCERATE CYCLIQUE (CDGP) ET/OU DE DERIVES DANS DES FORMULATIONS COSMETIQUES ET DERMATOLOGIQUES
Publication
Application
Priority
- DE 10040931 A 20000818
- EP 0109443 W 20010816
Abstract (en)
[origin: WO0215866A2] The invention relates to the inclusion of the low molecular weight substance (compatible solute), cyclic 2,4-diphosphoglycerate (cDGP), from extremophilic micro-organisms and/or derivatives of said compound, for example, an acid, a salt, or an ester, in cosmetic or dermatological formulations for protection of the skin from environmental influences and to increase the regeneration capacity. According to the invention, cyclic 2,4-diphosphoglycerate is implicated in active cell protection of the endogenous cell radical traps, antioxidants, the DNA, cell membranes and further cell compartments, by means of a protective effect of the above, against damaging environmental effects, for example, UV radiation, IR radiation, and environmental stress (thermal, chemical and physical). The compatible solute may serve as co-solvent and penetration improver for other active ingredients added to the cosmetic formulation, in order to not only stabilise the above in the cosmetic formulation, but also for active transport into deeper skin layers.
IPC 1-7
IPC 8 full level
A61K 8/00 (2006.01); A61K 8/14 (2006.01); A61K 8/27 (2006.01); A61K 8/37 (2006.01); A61K 8/44 (2006.01); A61K 8/49 (2006.01); A61K 8/55 (2006.01); A61K 8/58 (2006.01); A61K 8/65 (2006.01); A61K 8/67 (2006.01); A61K 31/665 (2006.01); A61P 17/16 (2006.01); A61P 31/00 (2006.01); A61P 31/12 (2006.01); A61Q 1/00 (2006.01); A61Q 1/04 (2006.01); A61Q 1/06 (2006.01); A61Q 1/10 (2006.01); A61Q 1/12 (2006.01); A61Q 5/00 (2006.01); A61Q 17/00 (2006.01); A61Q 17/04 (2006.01); A61Q 19/00 (2006.01); A61Q 19/10 (2006.01)
CPC (source: EP US)
A61K 8/14 (2013.01 - EP US); A61K 8/27 (2013.01 - EP US); A61K 8/375 (2013.01 - EP US); A61K 8/44 (2013.01 - EP US); A61K 8/49 (2013.01 - EP US); A61K 8/4913 (2013.01 - EP US); A61K 8/55 (2013.01 - EP US); A61K 8/65 (2013.01 - EP US); A61K 8/678 (2013.01 - EP US); A61P 17/16 (2017.12 - EP); A61P 31/00 (2017.12 - EP); A61P 31/12 (2017.12 - EP); A61Q 19/00 (2013.01 - EP US); A61Q 1/08 (2013.01 - EP US); A61Q 1/10 (2013.01 - EP US); A61Q 5/02 (2013.01 - EP US); A61Q 5/06 (2013.01 - EP US); A61Q 5/12 (2013.01 - EP US); A61Q 17/04 (2013.01 - EP US); A61Q 19/001 (2013.01 - EP US); A61Q 19/004 (2013.01 - EP US); A61Q 19/10 (2013.01 - EP US)
Citation (search report)
See references of WO 0215866A2
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
DOCDB simple family (publication)
WO 0215866 A2 20020228; WO 0215866 A3 20020606; AU 9546801 A 20020304; DE 10040931 A1 20020307; EP 1311237 A2 20030521; JP 2004506674 A 20040304; US 2004097543 A1 20040520
DOCDB simple family (application)
EP 0109443 W 20010816; AU 9546801 A 20010816; DE 10040931 A 20000818; EP 01976086 A 20010816; JP 2002520776 A 20010816; US 34496903 A 20030606